Back to Search
ANABELLA PASCUCCI, M.D.
M.D.
Dermatology Physician
NPI: 1558641936IndividualAccepts Medicare
Specialties, Licenses & Credentials
Dermatology PhysicianPrimary
Dermatology
Code: 207N00000X
A113352(CA)
CMS Specialties
PrimaryDERMATOLOGY
Education
UNIVERSITY OF CALIFORNIA, DAVIS SCHOOL OF MEDICINE
Class of 2009
Research & Publications (10)
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
PMID 17502132·Eur J Surg Oncol·2008
8-other
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
PMID 18343754·J Chemother·2008
3-trial
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
PMID 17429632·Cancer Chemother Pharmacol·2008
2-rct
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
PMID 18043134·Anticancer Drugs·2008
8-other
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
PMID 18620815·Cancer Treat Rev·2008
6-review
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
PMID 17535276·BJU Int·2007
8-other
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
PMID 17581304·Anticancer Drugs·2007
3-trial
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.
PMID 17437022·Br J Cancer·2007
3-trial
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients.
PMID 16786136·Oncol Rep·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 514 N PROSPECT AVE STE 103
REDONDO BEACH, CA 90277 - Phone
- (310) 937-8555
Quick Facts
- NPI
- 1558641936
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 17
- Publications
- 10
Are you this provider?
Claim Your Profile